Automated Detection of Informative Combined Effects in Genetic Association Studies of Complex Traits

por Tahri-Daizadeh, Nadia, Tregouet, David-Alexandre, Nicaud, Viviane, Manuel, Nicolas, Cambien, François, Tiret, Laurence
Publicado em 2003

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis

por Arroyo, Rafael, Bury, Denise P, Guo, Jennifer D, Margolin, David H, Melanson, Maria, Daizadeh, Nadia, Cella, David
Publicado no Mult Scler (2019)

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

por Okai, Annette F., Amezcua, Lilyana, Berkovich, Regina R., Chinea, Angel R., Edwards, Keith R., Steingo, Brian, Walker, Aljoeson, Jacobs, Alan K., Daizadeh, Nadia, Williams, Mitzi J.
Publicado no Neurol Ther (2019)

RANKL Inhibition With Denosumab Does Not Influence 3-year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosi...

por Samelson, Elizabeth J., Miller, Paul D., Christiansen, Claus, Daizadeh, Nadia S., Grazette, Luanda, Anthony, Mary S., Egbuna, Ogo, Wang, Andrea, Siddhanti, Suresh R, Cheung, AM, Franchimont, N, Kiel, Douglas P.
Publicado em 2014

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

por Adachi, Jonathan D., Bone, Henry G., Daizadeh, Nadia S., Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A., Wang, Andrea, Lin, Celia J. F., Wagman, Rachel B., Ferrari, Serge
Publicado no BMC Musculoskelet Disord (2017)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

por Wiendl, Heinz, Carraro, Matthew, Comi, Giancarlo, Izquierdo, Guillermo, Kim, Ho Jin, Sharrack, Basil, Tornatore, Carlo, Daizadeh, Nadia, Chung, Luke, Jacobs, Alan K., Hogan, Richard J., Wychowski, Linda V., Van Wijmeersch, Bart
Publicado no Neurol Neuroimmunol Neuroinflamm (2019)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

por Horáková, Dana, Boster, Aaron, Bertolotto, Antonio, Freedman, Mark S, Firmino*, Isabel, Cavalier, Steven J, Jacobs*, Alan K, Thangavelu*, Karthinathan, Daizadeh, Nadia, Poole*, Elizabeth M, Baker, Darren P, Margolin*, David H, Ziemssen, Tjalf
Publicado no Mult Scler J Exp Transl Clin (2020)

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

por Schemitsch, Emil H., Miclau, Theodore, Karachalios, Theofilos, Nowak, Lauren L., Sancheti, Parag, Poolman, Rudolf W., Caminis, John, Daizadeh, Nadia, Dent-Acosta, Ricardo E., Egbuna, Ogo, Chines, Arkadi, Maddox, Judy, Grauer, Andreas, Bhandari, Mohit
Publicado no J Bone Joint Surg Am (2020)

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

por Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S
Publicado no Mult Scler (2018)

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

por Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.
Publicado no J Neurol (2020)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

por Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Publicado no Ther Adv Neurol Disord (2021)

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of th...

por Bertolotto, Antonio, Arroyo, Rafael, Celius, Elisabeth G., Comi, Giancarlo, Havrdova, Eva Kubala, Honeycutt, William David, Hunter, Samuel F., Izquierdo, Guillermo, Kornek, Barbara, Miller, Tamara, Mitsikostas, Dimos D., Singer, Barry A., Ziemssen, Tjalf, Chung, Luke, Daizadeh, Nadia, Afsar, Salman, Hashemi, Lobat, Senior, Peter
Publicado no Neurol Ther (2020)

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

por Ziemssen, Tjalf, Bass, Ann D., Berkovich, Regina, Comi, Giancarlo, Eichau, Sara, Hobart, Jeremy, Hunter, Samuel F, LaGanke, Christopher, Limmroth, Volker, Pelletier, Daniel, Pozzilli, Carlo, Schippling, Sven, Sousa, Livia, Traboulsee, Anthony, Uitdehaag, Bernard M. J., Van Wijmeersch, Bart, Choudhry, Zia, Daizadeh, Nadia, Singer, Barry A.
Publicado no CNS Drugs (2020)

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studi...

por Comi, Giancarlo, Alroughani, Raed, Boster, Aaron L, Bass, Ann D, Berkovich, Regina, Fernández, Óscar, Kim, Ho Jin, Limmroth, Volker, Lycke, Jan, Macdonell, Richard AL, Sharrack, Basil, Singer, Barry A, Vermersch, Patrick, Wiendl, Heinz, Ziemssen, Tjalf, Jacobs, Alan, Daizadeh, Nadia, Rodriguez, Claudio E, Traboulsee, Anthony
Publicado no Mult Scler (2019)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma

por Bansal, Ashish, Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Blauvelt, Andrew, de Bruin-Weller, Marjolein, Corren, Jonathan, Sher, Lawrence, Guttman-Yassky, Emma, Chen, Zhen, Daizadeh, Nadia, Kamal, Mohamed A., Shumel, Brad, Mina-Osorio, Paola, Mannent, Leda, Patel, Naimish, Graham, Neil M. H., Khokhar, Faisal A., Ardeleanu, Marius
Publicado no Am J Clin Dermatol (2021)

Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

por Papapoulos, Socrates, Chapurlat, Roland, Libanati, Cesar, Brandi, Maria Luisa, Brown, Jacques P, Czerwiński, Edward, Krieg, Marc-Antoine, Man, Zulema, Mellström, Dan, Radominski, Sebastião C, Reginster, Jean-Yves, Resch, Heinrich, Ivorra, José A Román, Roux, Christian, Vittinghoff, Eric, Austin, Matthew, Daizadeh, Nadia, Bradley, Michelle N, Grauer, Andreas, Cummings, Steven R, Bone, Henry G
Publicado em 2012

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

por Bone, Henry G., Chapurlat, Roland, Brandi, Maria-Luisa, Brown, Jacques P., Czerwiński, Edward, Krieg, Marc-Antoine, Mellström, Dan, Radominski, Sebastião C., Reginster, Jean-Yves, Resch, Heinrich, Ivorra, Jose A. Román, Roux, Christian, Vittinghoff, Eric, Daizadeh, Nadia S., Wang, Andrea, Bradley, Michelle N., Franchimont, Nathalie, Geller, Michelle L., Wagman, Rachel B., Cummings, Steven R., Papapoulos, Socrates
Publicado em 2013